We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+21.26%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$3.77B
AUM Growth
+$720M
(+24%)
Cap. Flow
+$280M
Cap. Flow
% of AUM
7.43%
Top 10 Holdings %
Top 10 Hldgs %
22.38%
Holding
294
New
116
Increased
45
Reduced
52
Closed
77
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$115M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$93.9M |
| 3 |
NXP Semiconductors
NXPI
|
+$57.1M |
| 4 |
Eli Lilly
LLY
|
+$51.1M |
| 5 |
Qorvo
QRVO
|
+$47.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microchip Technology
MCHP
|
+$72.6M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$66.5M |
| 3 |
Amazon
AMZN
|
+$65.6M |
| 4 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$58.8M |
| 5 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$53.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 42.9% |
| 2 | Technology | 32.83% |
| 3 | Communication Services | 8.98% |
| 4 | Financials | 3.92% |
| 5 | Consumer Discretionary | 3.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SAGE
76
DELISTED
Sage Therapeutics
SAGE
| $16M | 0.42% |
184,558
-576
| -0.3% | -$42.5K |
|
77
Encompass Health
EHC
$11B
| $15.6M | 0.41% |
+237,515
| New | +$14M |
|
78
Estee Lauder
EL
$31.5B
| $14.9M | 0.39% |
+55,889
| New | +$13.4M |
|
79
ICU Medical
ICUI
$4.3B
| $14.9M | 0.39% |
69,259
-23,004
| -25% | -$4.46M |
|
80
Corcept Therapeutics
CORT
$11.9B
| $14.8M | 0.39% |
+565,892
| New | +$11.9M |
|
81
Edgewell Personal Care
EPC
$1.31B
| $14.7M | 0.39% |
+425,409
| New | +$13.8M |
|
82
Cisco
CSCO
$480B
| $14.3M | 0.38% |
+320,438
| New | +$13.2M |
|
83
Allogene Therapeutics
ALLO
$656M
| $14.3M | 0.38% |
567,539
+167,306
| +42% | +$5.45M |
|
84
Immunovant
IMVT
$8.08B
| $13.9M | 0.37% |
301,903
+160,733
| +114% | +$7.43M |
|
85
PMV Pharmaceuticals
PMVP
$62.4M
| $13.8M | 0.37% |
224,821
+17,400
| +8% | +$683K |
|
86
Eledon Pharmaceuticals
ELDN
$269M
| $13.7M | 0.36% |
+892,555
| New | +$17M |
|
|
LEAP
87
DELISTED
Ribbit LEAP, Ltd.
LEAP
| $13.7M | 0.36% |
+1,057,400
| New | +$12.9M |
|
88
Knowles
KN
$3.45B
| $13.3M | 0.35% |
722,979
-86,538
| -11% | -$1.45M |
|
|
NATI
89
DELISTED
National Instruments Corp
NATI
| $13.3M | 0.35% |
+302,674
| New | +$11.3M |
|
90
Perrigo
PRGO
$1.49B
| $13M | 0.35% |
+291,607
| New | +$13.5M |
|
91
Qualcomm
QCOM
$171B
| $13M | 0.34% |
+85,266
| New | +$11.9M |
|
92
Seer Inc
SEER
$122M
| $12.7M | 0.34% |
+225,532
| New | +$14.3M |
|
93
Zimmer Biomet
ZBH
$18.5B
| $12.2M | 0.32% |
81,738
-153,664
| -65% | -$21.7M |
|
94
Relay Therapeutics
RLAY
$4.26B
| $12.2M | 0.32% |
293,215
-58,608
| -17% | -$2.65M |
|
95
Legend Biotech
LEGN
$3.7B
| $12.1M | 0.32% |
+431,418
| New | +$12.4M |
|
96
DexCom
DXCM
$32.8B
| $12.1M | 0.32% |
130,992
+100,348
| +327% | +$8.96M |
|
97
Elanco Animal Health
ELAN
$12.8B
| $11.8M | 0.31% |
+383,325
| New | +$11.7M |
|
98
Avnet
AVT
$7.59B
| $11.7M | 0.31% |
333,271
+52,675
| +19% | +$1.56M |
|
|
HMCOU
99
DELISTED
HumanCo Acquisition Corp. Unit
HMCOU
| $11.6M | 0.31% |
+1,055,321
| New | +$11.7M |
|
100
Atea Pharmaceuticals
AVIR
$376M
| $11.5M | 0.31% |
+276,083
| New | +$8.9M |
|
Similar funds
PAM
TCIIS
UIM
VAI
Woodline Partners's Q4 2020 Portfolio in Review
As of Q4 2020, Woodline Partners held 294 positions worth $3.77B, up 24% from $3.05B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Woodline Partners deployed $280M of net new capital in Q4 2020, opening 116 new positions and adding to 45 existing holdings. Its largest new stake was Amgen: 500,520 shares worth $115M.
By sector, the portfolio is most concentrated in Healthcare at 43% of assets, down from 45% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $58.8M trimmed.
- Woodline Partners's largest Q4 2020 buy was Amgen: 500,520 shares worth $115M.
- Woodline Partners added most to Eli Lilly in Q4 2020, an estimated $51.1M increase.
- Woodline Partners's biggest Q4 2020 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $58.8M.
- Woodline Partners fully exited Microchip Technology in Q4 2020, selling an estimated $72.6M.
- Woodline Partners's ten largest holdings make up 22% of its $3.77B portfolio in Q4 2020.
- Woodline Partners opened 116 new positions and closed 77 in Q4 2020.
- Woodline Partners's portfolio value rose 24% quarter-over-quarter to $3.77B.
Based on Woodline Partners's 13F filing for Q4 2020, filed 16 Feb 2021.